1. Home
  2. News
  3. Mesoblast Limited
  4. 83% Survival in COVID-19 ARDS Patients with Remestemcel-L
More Mesoblast Limited news
Mesoblast LimitedASX: MSB

83% Survival in COVID-19 ARDS Patients with Remestemcel-L

Apr 24, 2020 at 12:24 AM EDT · Issued by Mesoblast Limited

Filed with ASX · Apr 24, 2020 at 12:24 AM EDT · 3 pages · English

On 6ix: 6ix.com/news/83percent-survival-in-covid-19-ards-patients-with-remestemcel-l

Watch Mesoblast's latest callMesoblast (ASX:MSB) Q4 2026 Earnings Call · Replay · Aug 26↗

Mesoblast Limited on 6ix

Story so far

  • FDA Clears IND for Remestemcel Use in COVID-19 ARDS PatientsApr 6, 2020
  • Mesoblast to Evaluate Remestemcel-L in COVID-19 Lung DiseaseMar 10, 2020
  • Day 180 Survival Outcomes In aGvHD Phase 3 TrialSep 20, 2018

Earlier from Mesoblast

  • US NIH Trials Network to Conduct COVID-19 Phase 2/3 TrialApr 8, 2020
  • FDA Clears IND for Remestemcel Use in COVID-19 ARDS PatientsApr 5, 2020
  • FDA Accepts BLA for RYONCIL and Agrees to Priority ReviewMar 31, 2020
  • Mesoblast to Evaluate Remestemcel-L in COVID-19 Lung DiseaseMar 9, 2020
  • Mesoblast Provides Half Year Results and Corporate UpdateFeb 26, 2020

Later from Mesoblast

  • Phase 2/3 Trial in COVID-19 ARDS Begins EnrollmentApr 29, 2020
  • MSB Completes Financing For Covid-19 ARDS ManufacturingMay 13, 2020
  • Remestemcel-L Improves Outcomes in Inflammatory Lung DiseaseJun 1, 2020
  • S&P DJI Announces June 2020 Quarterly RebalanceJun 11, 2020
  • FDA Advisory Committee Sets Review Date for Remestemcel-LJul 20, 2020
All Mesoblast news releases↗

Follow Mesoblast into a list and get an email when it puts out news.

Follow Mesoblast
  • About 6ix
  • Editorial & Sourcing
  • Corrections
  • Contact
  • Privacy
  • Terms
  • Disclaimer